A	B	C	D	E	F	G	H	I	J	K	L
1
2		Name	Indication	Approved	Competition	Economics	Admin	IP		Price	273
3		IV Remodulin	PAH	5/21/2002	Thelin, Ambrisentan, Ventavis, Tracleer, Flolan, NS-304	1	IV/SQ	Expired		Shares	46.846538	Q123
4		Tyvaso	PAH	7/30/2009	Ventavis	1	Inhaled			MC	12789.104874
5		Adcirca (tadalafil)	PAH	5/26/2009	Revatio	90%, LLY 10%	Oral			Cash	4629	Q123
6				Phase						Debt	800	Q123
7										EV	8960.104874
8
9
10
11						2001: beraprost failure.
12						Q1 2007: CDC reports on Remodulin sepsis issue
13						mid-2007: complete TRIUMPH-1 enrollment
14						October-November: TRIUMPH-1 data
15						Q2 2008: File Viveta NDA.
16						Mid-November 2008: FREEDOM-C oral Remodulin data.
17						7/30/2009: Tyvaso/Viveta PDUFA
18						?: Had antibiotic project?
19						January 31 2011: FREEDOM-M completes enrollment.
20						April 2011: begin 50-pt US safety trial of implantable pump
21						June 2011: FREEDOM-M results
22						Sept 2011: FREEDOM-C2 results
23						May 2011: FREEDOM-M Phase III study reports.
24						beraprost
25						Type V Collagen